



Euro BioFairs Compass

Winter 2015



Guide to Life Sciences Events

SPECIAL

Your Agenda for 2016

For more than 20 years euroPLX has been the world's most often held partnering conference for the pharma and biotech industries.

Productivity Breeds Success.

Success in partnering is a matter of choosing the most productive conference format.

Mark your calendar or register online now:

- ★ **euroPLX 60 Barcelona (Spain)***
March 7 + 8, 2016
Hotel Fairmont Rey Juan Carlos I
- ★ **euroPLX 61 Valletta (Malta)***
June 13 + 14, 2016
Hilton Malta, Portomaso (Valletta)
- ★ **euroPLX 62 Nice (France)****
November 21 + 22, 2016
The Hyatt Regency Nice Palais de la Méditerranée

* open for registration now

** open for registration as of 1 Dec 2015

www.europplx.com

Partnering for Pharma Deals



Langer Anger 75
69115 Heidelberg, Germany
ph. ++49 (6221) 4262960
meetyou@europplx.com



Since 1995. Made in Europe for the World.

Mark your calendar

EUROBIOFAIRS COMPASS Every manager, scientist or business developer has his very individual, specific network and so their must-attend events differ significantly. Where to meet potential new partners and how to widen the scope besides well-known terrain is quite difficult to find out. EURO BIOFAIRS COMPASS will help you navigate the European meeting jungle.



Three different worlds – the academic, the biotech and Big Pharma field – will meet at **BioFIT** in Strasbourg (1–2 December 2015) to initiate technology transfer and translation of early stage projects. As most of the 1,100 attendees seeking for partners come from academia, the chances are high of actually finding some new approaches. Attendees can schedule up to 30 one-to-one meetings. Additional round tables, panel discussions and presentations create the ideal climate for making contacts and new partnerships.

The emerging digital revolution in medicine will be the focus of the 9th edition of the **IP Conference in Life Sciences** (12 February 2016). Life sciences decision makers, IP and legal experts, business developers and investors will meet in Berlin to explore the market potential, impact on patients, as well as the patentability of apps, wearables, medical devices and other digital healthcare solutions. More information will be accessible shortly through registration at www.biocom.de/events/IP.

Insight on upscaling complex manufacturing processes – such as for novel gene and cell therapeutics, on quality control and analytics will be provided at the **6th Cell Culture World Congress 2016** (23–24 February 2016). The meeting, which will bring 350+ experts to Munich, comes in combination with the 2nd Downstream Processing World Congress and is an established meeting point for Big Pharma representatives.

Keep your suitcase packed

Vienna will be in the limelight of Companion Diagnostics developers. **The Austrian Biomarker Symposium** (10–11 March, Vienna) explicitly wants to be a forum for biotechs seeking new market opportunities. Attendants from academia will learn about biomarker validation and report on new developments in point-of-care diagnostics.

A week later, on 18–19 March, all clinical research whiz kids should prick up their ears – and head to Berlin. Learn

how to improve your workflow in an ever changing regulatory environment at the DGPharmMed's **Annual Congress on Pharmaceutical Medicine**. Update your knowledge on various topics such as the EU clinical trials regulation, patient involvement, pharmacovigilance and much more.

Chemical and biotech engineers should block off the days from 5–6 April. At the **International Conference on bio-based materials** in Cologne, experience at first hand exactly how an established market is being reshaped by visionaries from the chemicals and plastics businesses.

For those in the healthcare sector, a visit to Hamburg might be unavoidable. This year's **DIA annual EuroMeeting** on 6–8 April will attract 2,500 stakeholders, all interested in health product development. With the DIA Clinical Forum and the Clinical Forum Exhibition under one roof, the Congress Centre Hamburg is certain to turn into a global healthcare village.

Shortly before the G20 heads are expected to sign off the WHO's Global Action Plan against Antimicrobial Resistance, the anti-infectives and microbial community will gather at **ECCMID** in Amsterdam. From 9–12 April, 10,000+ experts will present the latest antimicrobial strategies in 150 top-notch lectures, as well as more than 2,000 posters.

A smaller event that still has a major impact kicks off on 12 April in Basel hosting the nation's most important biotech event, the **Swiss Biotech Day**. As in previous years, the new Swiss biotech report will shine a light on the industry's status in the country. Due to the growth of the sector, the Swiss Biotech Day moved to Basel Congress Centre last year. ■



1 – 2 December, 2015
Palais de la Musique et des Congrès
Strasbourg, France

One-stop-shop

BIOFIT 2015 With 1,100 attendees, 30 countries represented, 900 licensing opportunities and 2,500 one-to-one meetings, BioFIT emerges as the leading European partnering event for Open Innovation and technology transfer in the life sciences.

With the highest attending rate of academia, TTOs and research institutes, BioFIT is the place where academia-industry collaborations get started. Together with big pharma, emerging biotech companies, medtech and diagnostics companies, BioFIT operates as a platform to build partnerships for all public and private stakeholders.

Created in 2010 to highlight the importance of cooperation between academics, biotechs and industry in the de-

velopment of tomorrow's innovations; BioFIT has now emerged as the meeting point for collaborative research and tech transfer deals. In order to meet the expectations of the participants, BioFIT is now organised on an annual basis together with the TTO Conectus Alsace and Alsace BioValley Cluster. The 4th edition of the event is to be held for the first time in Strasbourg.

Through the business convention, the attendees can schedule up to 30 one-to-

one meetings over the two days. They can also manage their schedule to save time and attend panel discussions or presenting technologies sessions running on the sideline of the partnering activity.

These round tables and panel discussions feature 70 high-level speakers (Big Pharma representatives, TTO managers, biotech CEO, investors, etc.). One plenary session and 14 round tables will be offered to discuss hot topics on the best practices in collaborative research, technology transfer and financing innovation at an early stage.

Moreover, the posters and presenting technologies sessions, featuring nearly 100 posters and 32 oral presentations, are the perfect way to discover the latest innovations to be licensed in immunology, oncology, cardio metabolic and infectious diseases, vaccines, devices and imaging. ■

Bienvenue!

Welcome BioFIT attendees meet every year to engage in new partnerships,



foster the emergence of collaborative projects and intensify the flow of licenses in the field of life sciences. We will be pleased to welcome you in Strasbourg 2015

or Lille 2016 – and are confident you will enjoy the intensive days of fruitful meetings and partnership opportunities with the leading life sciences stakeholders.

Etienne Vervaecke

General Commissioner of BioFIT and Eurasanté General Manager

Detailed information about the Alsatian life sciences sector and the BioFIT event is available at www.biovalley.com and www.biofit-event.com.

QUICK FACTS

BioFIT will be held for the first time in the French-German-Swiss Biovalley. Discover within a 200km² area:

- > 600 life sciences companies
- > 15,000 scientists
- > 6 Nobel Prize winners

BioFIT event, please contact:

Anaïs Schoreel, Business developer
Tel.: +33 (0)3-59-39-01-81
aschoreel@eurasanté.com



Biofit

FOSTERING
INNOVATION
& TRANSFER

STRASBOURG **2015** - FRANCE



EXHIBITION



BUSINESS
CONVENTION



CONFERENCES



PRESENTING
SESSIONS

Join the leading partnering event in Europe
dedicated to Tech Transfer & Open Innovation
in Life Sciences and
get 25% off with the promotional code

25_EUBioN_BF%

SEE YOU
NEXT YEAR

in Lille - France
NOV 30&DEC 1, 2016

SAVE
THE
DATE



Organized by



Partner





12 February, 2016
French Embassy
Berlin, Germany

QUICK FACTS

Highlights

- › Insights into digital health market
- › Potential for clinical trials
- › Discussion of legal issues

Contact

BIOCOM AG
 Phone: +49(0) 30 264 921 53
www.ip-conference.de

Digital health matters

BERLIN CONFERENCE ON IP IN LIFE SCIENCES In its 9th year, the leading event for European life science decision makers will focus on the potential and challenges that digital health solutions offer biotech and pharma companies today, and in the future.

In light of an ongoing digital change progress, the Berlin Conference in 2016 is designed to provide deep insights into the digital health market environment across Europe and beyond.

The implementation of new digital tools within drug development and clinical trial settings is more relevant today than ever before. Almost daily, new collaborations between phar-

ma, biotech and IT companies are announced across Europe. In cooperation with the French Embassy, the Berlin Conference on IP in Life Sciences will discuss the most important IT solutions, which provide pharma and biotech companies with new instruments to deliver a better experience to patients, to improve clinical outcomes and to reduce total costs. In particular, the relevance of digital solutions

for clinical research – such as virtual clinical trials or online patient communities – will be highlighted. Further topics covered during the conference include the impact of IT on life science R&D in general, as well as on translational medicine. Furthermore, legal issues regarding the use and the patenting of new digital health products and the challenge of data protection concerns will be covered by various European experts in the field. In addition, digital health investors and start-ups will talk about the economic relevance of new business models and opportunities. Up to 200 participants from the business, legal and scientific fields are expected to join the conference. ■

Highlights of the Conference Programme

Keynote:

François Nicolas,
 Head of Integrated Care,
 Diabetes & Cardiovascular,
 Sanofi

Market overview:

Thilo Kaltenbach,
 Partner, Healthcare & Pharma,
 Roland Berger

Legal issues:

Jürgen Meier, Vossius & Partner
Michele Wales, InHouse Patent
 Counsel, LLC
Jean-Baptiste Mozziconacci,
 Institut national de la propriété
 industrielle (INPI)

Trends & Challenges:

Friedrich von Bohlen,
 Molecular Health

Christian Gossens,

Pharmaceutical Research and Early
 Development, Roche (invited)
Philippe Gesnouin,
 Institut national de recherche en in-
 formatique et en automatique (INRIA)

Investors & Start-ups:

Thierry Laugel, Kurma Partners
Alexander Puschilov, viamedo

9th Berlin Conference on IP in Life Sciences

Digital Health Solutions



12 February 2016, French Embassy Berlin, Germany

The Berlin Conference on IP in Life Sciences has become a must-attend for Life Science decision makers, IP and legal experts, business developers and investors. The upcoming event will explore the potential of digital health technologies for the Life Sciences sector and discuss relevant interfaces of the pharma, biotechnology, medical care and IT industries.

- › Digital Health Market – Industry Overview & Financial Insights
- › New Role of Patients – From Virtual Clinical Trials to Online Patient Communities
- › Patents, Legal Aspects – The Challenges of Bringing e-Health Products to the Market
- › Outlook – Scientific Breakthroughs, Research Alliances & Public-Private Partnerships
- › Start-up Pitch – Investor’s Talk & New Business Opportunities

Please find the constantly updated program and a registration form at www.IP-Conference.de

Principal Partner:



Sponsor:



Supporting Partner:



Media Partner:





**Cell
Culture World**
Congress 2016

23 – 24 February 2016
Sofitel Munich Bayerpost
Bayerstr. 12, Munich, Germany

Bioprocess insight

CELL CULTURE AND DOWNSTREAM PROCESSING WORLD CONGRESS 2016

Bringing together industry leaders, focusing on innovation and development. Showcasing new technologies and new methods of quality control and for the manufacturing of new formats.

How can we move from research scale production to clinical and commercial scale with new cell and gene therapies? It starts by bringing together new and experienced players from the bioprocess community to find the best partners and the right knowledge to overcome the barriers preventing therapies from making it from bench to bedside. Bringing people together to tackle issues ranging from regulatory approval, scalability is-

suces through to the high cost of manufacturing. This February, Cell Culture World Congress 2016 and Downstream Processing World Congress 2016 are aiming to do just that, bringing together over 350+ industry experts to discuss the next steps in bioprocess advancement.

Key Themes

Amongst other topics, see the newest methods in quality control and analytical technology, examine how continuous manufacture and bioprocess has been physically implemented in case studies from key players, and explore the newest methods of CRISPR/Cas9, genomics and cellular gene editing. We also have expert led round tables, allowing participants to learn from leading providers and authorities in the manufacturing space. In addition, the congress will provide you with the opportunity to exchange knowledge and ideas with your peers in these facilitated discussion sessions.

> QUICK FACTS

In brief

Two days
350+ participants
50+ speakers
20 countries +
On floor innovation showcase

Registration

Andrew Li
Phone: +44 20 7827 4150
Andrew.Li@terrapinn.com

Up & downstream

Welcome from the chair

I am delighted to welcome you to the 6th annual Cell Culture World Congress 2016 and the 2nd Downstream Processing World Congress 2016, bringing together experts from the bioprocess community.



We are honoured to be welcoming back key players in the industry such as Novartis, Genentech, GlaxoSmithKline and AstraZeneca, and keynote speakers such as Sam Wadsworth, Dimension Therapeutics and Dr. Yogesh Waghmare, Genzyme. I myself am looking forward to presenting on "Viral DSP development, stem cell and cell therapy purification and concentration".

The programme is rich and varied with six keynote presentations and 50+ speakers in total. We also have the new on floor innovation showcase which will consist of targeted sessions exploring the most innovative new platform technologies being developed towards bioprocess and process development.

I hope that you will find the conference and your stay in Munich valuable, and I look forward to welcoming you in February.

Prof. Dr. Manuel Carrondo

Director
IBET

6th annual

Cell Culture World

Congress 2016

23-24 February 2016
Sofitel Munich Bayerpost, Munich

Enhancing and innovating your cell culture process

Over 300 key stakeholders, decision makers, influencers and end users from across pharma, biotech and academia will be coming together to discover the success stories and challenges faced in cell culture production, continuous manufacture, quality control/analytics and accelerated process development.

OVER 30 SPEAKERS INCLUDE:

Dr Herve Broly

Vice President Biotech Process Development, **Merck Serono**

Mr Mark Angelino

Vice President of Pharmaceutical Sciences, **bluebird bio**

Mr Bo Kara

Head Process Development, **GSK**

Dr Josh Grieger

Co-founder and Vice President of Manufacturing, **Bamboo Therapeutics**

Dr Lorenz Mayr

Vice President, Reagents & Assay Development, **AstraZeneca**

Dr Stefan Wildt

Vice President & Global Head Technical Research and Development, **Novartis**

DAY 1

CRISPR, Cell Line Development & Manufacturing New Formats

- Manufacturing immunotherapy: new manufacturing paradigm for biomanufacture
- A commercially viable novel CMC approach to bioprocessing AAV for rare diseases
- Manufacturing ex-vivo cell & gene therapy for rare disease and oncology applications
- Roundtable Discussions
- Using CRISPR for cell line development for preclinical drug discovery
- Application of omics data, screening and genome editing to improve CHO cell factories
- Genetically ensuring stability of CHO cell line
- The potential of CRISPR to engineer an improved CHO cell platform
- Chromosome identification and stability in Chinese Hamster Ovary cells
- DNA Sequencing of cell lines to increase yield, quality & time for production of biologics
- Building a 'tool box' of various genetic and process related tools to fine tune cell line to your product
- Next-gen assays for profiling virus & cell production for gene therapy
- GMP considerations for autologous CAR-T cell therapy
- CMC considerations for manufacturing gene and CAR-T cell therapies
- GMP production strategies for lentiviral vectors
- Process development for upstream AAV manufacture

DAY 2

Continuous Bioprocess, Control and Design

- Media development toward high cell density, high productivity and low perfusion rates for continuous biomanufacturing platforms
- Rethinking downstream process monitoring for implementation of continuous bioprocessing
- Update on ballroom concept facilities for continuous manufacturing
- Designing the biomanufacturing of the future
- Using process development to control the quality of biopharmaceuticals
- Considerations for scaling upstream fed-batch processes
- Optimization of perfusion cultures for bio-manufacturing
- New paradigms in bioproduction culture media development
- Exploring the effects of cell culture media on therapeutic protein quality: an update
- In-depth characterisation analytics in continuous biomanufacturing
- Advanced multivariate analysis for the production of biosimilars
- Process development: ensuring the highest/sustainable level of product quality
- Automation tools and logistics: solutions for quality control
- Outsourcing manufacture to the Asia-Pacific region
- Manufacturing a viral vector for gene therapy at the 2000L scale



Register now and get a 15% discount! terrapinn.com/attendCellCulture2016



10 – 11 March, 2016
Tech Gate Vienna
Vienna, Austria

Early Dx saves lives

BIOMARKER SYMPOSIUM The Austrian Biomarker Symposium 2016 on Early Diagnostics provides insight knowledge and best practices for biomarkers and technologies in a variety of diseases and diagnostic applications. Speakers from academic and clinical institutions as well as industry will cover key topics in personalised medicine.

The past Austrian Biomarker Symposiums attracted diverse experts from biotech, public institutions and pharma. During the two-day event, international experts will address not only the discovery and validation of early diagnosis biomarkers for personalised medicine but also report on new developments in biomarker as well as point-of-care technologies. Key note speaker Parag Mallick (Stanford University, USA) will give a lecture on systems bi-

ology approaches for the discovery of biomarkers for early cancer detection and thereby open a scientific track fully dedicated to big data and systems biology. A second keynote speech given by Ulf Landegren (Uppsala University) will focus on new cutting edge protein technologies.

The symposium's target audience includes those interested in biomarkers, as well as anyone who focuses on early diagnostics, systems biology or

new technologies for biomarker and/or point of care applications.

Experiences and challenges

Internationally well recognised speakers from academia and industry will particularly address experiences and challenges in minimally invasive diagnostic biomarker research during five dedicated scientific sessions:

- Personalised Medicine & Early Diagnosis
- Big Data & Systems Biology
- Novel Sensor Technologies & Point of Care Diagnostics
- Circulating Biomarkers
- Cutting Edge Biomarker Technologies

The conference supports companies in their quest for unveiling new market opportunities and gives excellent visibility to key opinion leaders and decision makers during the industry exhibition. ■

Take opportunity



agnosis and individualised treatment decisions. A major goal of the 3rd Aus-

Greeting *Age-related diseases and cancer pose new challenges for medicine and health systems requiring novel molecular biology methods for early diagnosis*

trian Biomarker Symposium is to encourage the biotechnology community to apply and advance biomarker technologies. Biomarkers herald a new age in the field of personalised medicine. Join us for excellent research, industry expertise and great networking opportunities.

Martin Weber

Head of Business Unit
Molecular Diagnostics
AIT Austrian Institute of Technology

➤ QUICK FACTS

When and where?

10-11 March, 2016

Tech Gate Vienna
Donau City Straße 1
1220 Vienna, Austria


Contacts

Phone: +43(0) 50550-4406
www.biomarker-development.com

3rd Austrian Biomarker Symposium 2016

Early Diagnostics

March 10 – 11, 2016
Tech Gate Vienna, Austria



Key Topics

- Personalized Medicine & Early Diagnosis
- Big Data & Systems Biology
- Novel Sensor Technologies & Point of Care Diagnostics
- Circulating Biomarkers
- Cutting Edge Biomarker Technologies

Keynote Speakers

Parag Mallick, Canary Center at Stanford University, USA
Ulf Landegren, Uppsala University, SE

www.biomarker-development.com





17 – 18 March, 2016
Steigenberger Hotel Am Kanzleramt
Berlin, Germany

Leaving classic paths

32ND ANNUAL CONGRESS ON PHARMACEUTICAL MEDICINE The landscape in drug and medicinal product development is always changing. In order to be successful we need to identify, understand and utilise our opportunities. At this congress, key topics helping to realise these possibilities will be addressed.

This year's event will shine a light on opportunities in drug and product development. In six symposia, more than 20 experts will share their knowledge and give insight on how they utilised opportunities in their business. In addition, a panel discussion will address what happens when Clinical development meets Finance & Controlling.

Authorities in different regions sometimes focus on regional specific aspects. Considering these and iden-

tifying the right strategy in drug and product development is challenging. Understanding the authorities' perspectives is the first step enabling us to find the right strategy for being successful and efficient. At the 32nd Annual Congress, we will learn more how this can be achieved with respect to scientific advice in the US and EU.

It is not unusual that we are facing new regulations, but still we do not know exactly how to cope with obli-

gations originating from regulations which came into force recently. Sharing best practices in conducting clinical trials and pharmacovigilance helps to manage current challenges. But we also need to be prepared for upcoming tasks like the implementation of the standards for the identification of medicinal products (IDMP) and the new regulation on clinical trials. Regarding the latter, we will gain insight in first experiences from authorities and ethic committees about the pilot project of common assessment according to the new regulation.

In addition, cooperation between Pharma and non Pharma is becoming more relevant and will be addressed at this congress for the first time.

DGPharMed is proud to present this impressive snapshot of the current situation in pharmaceutical medicine, and looks forward to welcoming you in Berlin on 17–18 March, 2016. ■

Give it a go!

Welcome *In an ever changing regulatory environment, development of medicinal products and medical devices still opens chances to those who recognise, understand and use them. At the 32nd Annual Congress on Pharmaceutical Medicine, we*



will give you an update on best practices in clinical development, but at the same time examine chances and potentials beyond the usual well-known paths. On behalf of the programme committee and as the DGPharMed host, I cordially invite you to join us at the Steigenberger Hotel in Berlin on 17 – 18 March for an active and lively discussion of our current and future opportunities. The programme will soon be available online.

Susanne Kienzle-Horn
 Directorate DGPharMed-Fachbereiche

QUICK FACTS

Exhibition

Interested? Please contact:
aussteller@degepe.eu

Congress rationale

Leave classic paths, take smart risks – and learn from orphan drugs, immune and cell-based therapy experts!

info@dgpharmed.de
www.dgpharmed.de/veranstaltungen/



32nd DGPharMed Annual Meeting

*Drug and product development today: Identification,
understanding and utilization of opportunities*

March 17–18, 2016 – Berlin, Germany

Symposia

- » Scientific advice: US vs. EU – How do they fit together?
 - » Utilization of opportunities: Partnering between Pharma and non Pharma
 - » Clinical trials – Best Practices Update
 - » Clinical development meets Finance & Controlling – clash or cooperation?
 - » Immune therapy – Where are we?
 - » Beyond classic ways of thinking: Specialties in product development
 - » European legislation: Learnings and what we are facing next
- Please note: the official conference language will be German*



Conference Venue

Steigenberger Hotel Am Kanzleramt
Ella-Trebe-Straße 5 • 10557 Berlin
www.steigenberger.com


Congress Fees

Members:
Non-Members:

Early-Bird-Rate	Booking from
until January 15 th , 2016	January 16 th , 2016
490,- €	590,- €
640,- €	740,- €

Organizing committee

Hoda Tawfik, Axel Mescheder, Stephan Rapp,
Daniel Sehrt, Carsten Wieser



For further information: info@dgpharmed.de · www.dgpharmed.de

Fax reply

+49 211 49767-29

I am interested in participating the
32nd DGPharMed Annual Meeting –
please send me the program.

.....
Name

.....
Street

.....
Postal code City

.....
E-mail



5–6 April 2016 + 7 April, 2016*
(*Bio-based Start-up Day)
Maternushaus, Cologne, Germany

Go bio-based!

INTERNATIONAL CONFERENCE ON BIO-BASED-MATERIALS Slated to take place from 5-6 April 2016 in Cologne (Germany), the 9th International Conference on Bio-based Materials will bring an estimated 300 participants and 30 exhibitors up to speed on the latest developments.

This year's conference is aimed at providing international major players from the bio-based building blocks, polymers and industrial biotechnology with an opportunity to present and discuss their latest developments and strategies. Along with its attendant exhibition, the event will bring together newcomers and experts with leading companies in the sector.

One goal is to address innovative developments in the industry, with presentations focused on areas like lignin, polyhydroxyalkanoates (PHA) and cellulosic

fibres. New bio-based building blocks and polymers are key drivers of innovative and sustainable developments in the industry as a whole. The latest news on new biomass utilisation pathways beyond drop-ins and new biorefinery concepts will also be a big draw at the conference.

Alongside leading companies, representatives from political bodies and associations will be on hand at the event, since strengthening the bio-based economy requires the right regulatory framework. That's why another focus will be

the latest national and regional policies, strategies and visions.

The Innovation Award Ceremony is another highlight at the event. The "Bio-based Material of the Year 2016" will be awarded to innovative young bio-based chemicals and materials industry actors who have launched new bio-based products on the market. Conference participants will choose the three winners.

After last year's great success, a new event will take place on 7 April 2016. Nova-Institute's Start-Up Day has been developed into a great event of its own, the Bio-based Start-up Day. High-potential start-ups from the field of bio-based chemistry, polymers and biotechnology are invited to present themselves to industry and investors. In cooperation with prestigious partners, conference organiser nova-Institute is set to provide a perfect platform and meeting point for networking between start-ups, established companies and investors. ■

Get involved

GREETING *The 9th International Conference on Bio-based Materials in Cologne is one of the biggest events on bio-based building blocks, polymers and industrial biotechnology in Europe. This year we expect 300 participants and 30 exhibitors to attend. Leading companies will be*



on hand. A special highlight will be the participant selection of the "Bio-based Material of the Year 2016".

Don't miss the "Bio-based Start-Up Day", 7 April 2016 – this year an event of its own, with high-potential start-ups from the field of bio-based chemistry, polymers and biotechnology.

We're looking forward to meeting you in the spring of 2016.

Michael Carus
CEO
nova-Institute

QUICK FACTS

ONLINE REGISTRATION

www.bio-based.eu/conference

CONTACT

Dominik Vogt
dominik.vogt@nova-institut.de

VENUE

Maternushaus
Kardinal-Frings-Str. 1-3
50668 Cologne

9th International Conference on Bio-based Materials

5–6 April 2016, Maternushaus, Cologne, Germany

Special Topics: ++ Lignin ++ Polyhydroxyalkanoates (PHA) ++ Innovation Award "BIO-BASED MATERIAL OF THE YEAR 2016"



HIGHLIGHTS OF THE WORLDWIDE BIOECONOMY: POLICY AND MARKETS – BIO-BASED BUILDING BLOCKS AND POLYMERS – BIOREFINERIES AND INDUSTRIAL BIOTECHNOLOGY

This conference aims to provide international major players from the bio-based building blocks, polymers and industrial biotechnology industries with an opportunity to present and discuss their latest developments and strategies. Representatives of political bodies and associations will also have their say alongside leading companies.

The 9th International Conference on Bio-based Materials builds on successful previous conferences. 300 participants and 30 exhibitors mainly from industry are expected!

Entrance Fee

Conference incl. Catering,
plus 19% VAT

1 st Day Conference 5 April 2016	2 nd Day Conference 6 April 2016
490 €	440 €
790 €	

Venue & Accomodation

Maternushaus Cologne, Germany
Kardinal-Frings-Str. 1–3, 50668 Cologne
+49 (0)221 163 10 | info@maternushaus.de

Contact



Dominik Vogt
Exhibition, Partners,
Media partners, Sponsors
+49 (0)2233 4814-49
dominik.vogt@nova-institut.de



BIO-BASED START-UP DAY

7 April 2016 · Maternushaus · Cologne · Germany

High-potential start-ups from the field of bio-based chemistry, polymers and biotechnology are invited to present themselves to industry and investors! www.bio-based.eu/startup

Organiser



www.nova-institute.eu

Book now

EARLY BIRD – 15% off till end of 2015.
Use the discount code **early15**



www.bio-based.eu/conference



DIA DEVELOP
INNOVATE
ADVANCE

6 – 8 April, 2016
CCH, Hamburg,
Germany

Win by being IN?

28TH ANNUAL EUROMEETING 2016 INnovation – Do You Win by being IN? In a world in which new therapies are being developed at a phenomenal rate, is innovation always the answer? The 28th Annual DIA EuroMeeting brings stakeholders together to collaborate on when, where and how innovation leads to advances in healthcare product development.

The event will give you the chance to discuss many of the major trends occurring in healthcare, from patient engagement in clinical trials to proactive lifecycle management. The themes at the EuroMeeting 2016 take into account how all players along the product development life cycle, as well as societal needs impact the development process. A major focus will be how to involve patients in our activi-

ties; on how to provide them with objective and comprehensive information on medicinal products, and also on how to incorporate their perspective on decision making.

From patient tools to legislation

Additionally, the themes directly address the interdependencies of how policy decision makers and regulators anticipate, evaluate and adjust guidelines accordingly. The 2016 EuroMeeting provides the premier platform to exchange ideas with thought leaders and to build your professional network. The sessions will cover pharmaceuticals, biotechnology and medical products. It is an opportunity to exchange views and to discuss new technologies, new legislations and their implementation, as well as new information on patient tools in a collegial environment where improving health is the common goal. A wide variety of sessions will be offered, with topics ranging from early development to market access. ■

▶ QUICK FACTS

Highlights

2,500 anticipated total attendance
100+ Sessions
300+ Speakers
7,000 m² of exhibition space
160+ anticipated exhibitors

Contact

EMEA@DIAGlobal.org
Phone: +41 61 225 51 51
www.DIAGlobal.org/EM2016

A common goal

GREETING We are delighted to announce that the DIA 28th Annual EuroMeeting will be held in Hamburg, on 6–8 April, 2016.

Patients and their families expect to receive medicinal products of a high standard that can make a significant contribution to their health and well-being. The early exchange of information between all stakeholders in an open fashion is a key factor in achieving this common goal. The DIA 28th Annual EuroMeeting in Hamburg, 'gateway to the world', is the perfect place to exchange scientific knowledge. It provides an opportunity for us to learn from each other and to work in partnership to improve the health of society. To this end, we are honoured to serve as Programme Co-Chairs of this important meeting.

The DIA Annual EuroMeeting is a forum for you to discuss ideas, challenges and opportunities for therapies in the 21st Century. Together with our DIA colleagues, we hope you will join us in Hamburg.



Kemal Malik, Member of the Board of Management, Bayer, Germany (left)
Karl Broich, President BfArM, Germany (right)

DIA 28th Annual EuroMeeting

INnovation • Do You Win by Being IN?

6-8 April 2016 | CCH | Hamburg, Germany

Register
now

In a world in which new therapies are being developed at a phenomenal rate, is innovation always the answer?

The DIA 28th Annual EuroMeeting brings stakeholders together to collaborate on when, where and how innovation leads to advances in health care product development. Example themes include: Clinical Trials; Life Cycle Benefit/Risk Management; Availability of Medicinal Products; eHealth / Big Data and Pharmacovigilance.



Networking Receptions

Networking is an integral part of the EuroMeeting.

With over 15 hours dedicated to networking, you will have various touchpoint opportunities to engage with existing contacts and make new connections.

Exhibiting Opportunities Available

Interact face-to-face with your future customers.

Contact us for more information and to book your space
EMEA.Exhibition@DIAglobal.org | Tel. +41 61 225 51 51

For more information or to register, visit www.DIAglobal.org/EM2016

DEVELOP.
INNOVATE. ADVANCE.

DIA provides a comprehensive catalogue of conferences, training courses, scientific publications and educational materials dedicated to advancing healthcare product development.

DIA DEVELOP
INNOVATE
ADVANCE

DIA Europe, Middle East & Africa
Küchengasse 16
4051 Basel, Switzerland

Basel, Switzerland | Beijing, China | Horsham, PA, USA | Mumbai, India | Tokyo, Japan

Discover new opportunities at DIAglobal.org



26th ECCMID

9 – 12 April, 2016
RAI Amsterdam
Netherlands

Update on infection

ECCMID 2016 For a quarter of a century, infection specialists have gathered at ECCMID to learn about the latest innovations in their field, exchange ideas and network with colleagues from all parts of the world.

The programme committee is once again preparing a series of some 150 top-notch presentations, including key-note lectures, symposia and educational sessions as well as more than 2,000 posters. Specialists from all disciplines in medical microbiology, infectious diseases, infection control and epidemiology will present research projects and discuss the most recent developments.

We expect over 10,000 participants who are keen to learn about the latest research, therapeutic approaches

and strategies in the battle against infectious diseases. Microbiologists, clinicians and public health experts will have the opportunity to exchange ideas on how to translate research findings into diagnostic tools, medicines, policies and training and thus effectively deal with the world's most pressing infection problems.

Top sessions include scientific symposia with winners of ESCMID's Excellence and Young Investigator awards as well as oral presentations on ground-breaking findings. The key-

notes will include lectures on novel approaches to vaccines, the microbiome, and tuberculosis, or on the economic impact of drug resistance and the effect of non-human antibiotics on public health.

Young professionals will have the opportunity to discuss ideas and projects with renowned experts. They may attend educational workshops and Clinical Grand Rounds, and for the first time, sessions dedicated to nurses. For the second year, ECCMID will feature a pipeline corner where smaller companies are offered a platform to present early-stage antimicrobial therapies.

With the healthcare challenges we are facing today, it remains crucial for professionals from clinical settings, microbiology and epidemiology to attend this event where we will discuss and disseminate evidence of advancements for better prevention and control of infectious diseases. ■

Join the experts

GREETING We invite you to the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held in Amsterdam, from 9 to 12 April 2016. The research and recommendations presented at the world's largest congress focused on infectious diseases and clinical



cal microbiology help improve diagnosis and prevention of infection, and the clinical care given to patients with infectious disease. Discussions on this vibrant platform not only raise awareness of emerging scientific questions; they also have a significant impact on best practices and international policies. We look forward to seeing you, along with thousands of your colleagues from around the globe in Amsterdam.

Winfried V. Kern
ECCMID Programme Director

QUICK FACTS

Programme
www.eccmid.org

Registration
Ms Dana Daabul
26th ECCMID
Kenes International –
Registration

Phone: +972 39 727538
Email: registration@eccmid.org



SEE YOU AT

26th **ECCMID**

Amsterdam, Netherlands

9–12 April 2016

ABSTRACT SUBMISSION DEADLINE: 29 NOVEMBER 2015

www.eccmid.org

Contact

Scientific Secretariat

26th ECCMID 2016
ESCMID Executive Office
P.O. Box 214
4010 Basel, Switzerland
eccmid@escmid.org

Venue

RAI Amsterdam
Postbus 77777
NL 1070 MS Amsterdam
The Netherlands
www.rai.nl/en

Congress Secretariat

Kenes International
Rue François-Versonnex 7
1207 Geneva, Switzerland
congress.admin@eccmid.org





SWISS+
BIOTECH™

12 April, 2016
Congress Center Basel
Basel, Switzerland

At the hub of biotech

SWISS BIOTECH DAY 2016 For the 18th year running, the leading biotechnology conference in Switzerland will offer a high-caliber meeting point for top-ranking representatives from the Central European life science sector.

One Nation, Once Cluster – nowhere does the truth of this Swiss claim become more apparent than at the Swiss Biotech Day. Driven by the annual general assembly of the Swiss Biotech Association (SBA), the springtime event is in a class of its own. The Swiss Biotech Day brings together more than 500 senior executives from the country's biotech companies and senior scientists from leading academic institutions. Organised by BIOCUM AG and the

SBA, the event's 2016 programme will again start off with keynote addresses by renowned members of the life science community. Another highlight on the agenda will be the presentation of the Swiss Biotech Report 2016.

In the afternoon, parallel sessions – presented by partners of the Swiss Biotech Day – will offer insights into more specific issues within the life sciences. An all-time favourite, the "Analyst & Investor" track will focus on the analyses

and predictions of publicly listed biotech companies as well as other opportunities in biotech financing. The track "Innovation in Healthcare" will again feature biotech startups presenting new therapeutic approaches. The track "Hotbeds in Biotech" will be supported by Switzerland Global Enterprise. An integral part of the conference will be the one-on-one partnering and the company showcases. Both will give attendees the opportunity to meet top-ranking representatives of the Central European life sciences.

Due to the rising numbers of attendees, the Swiss Biotech Day moved to a new venue last year. In 2016, the event will also take place at the Congress Center Basel, which has long been a life science cluster. As always, the event targets entrepreneurs, investors, research units, analysts, political decision makers and additional industry stakeholders. ■

A must attend



land. Now in its 18th year, the Swiss Biotech™ Day is a must attend one-day

Welcome *Biotechnology is a growing field within the life sciences and commands a driving position globally. The industry contributes positively towards the GDP of Switzerland.*

event. After receiving positive attendee feedback on the location, Swiss Biotech™ once again welcomes you to Basel Conference Center. 58SBA members will meet up for the Annual General Assembly (by invitation only) and enjoy the presentations and networking opportunities. Attendees will have unique opportunities to meet with stakeholders and friends. There will also be a partnering section at the event.

Domenico Alexakis
CEO, Swiss Biotech Association

QUICK FACTS

Highlights

- › Keynotes by industry authorities
- › Swiss biotech report 2016
- › In-depth parallel sessions
- › One-on-one partnerings

Contact

Swiss Biotech Association
Phone +41-43-508-1121

www.swissbiotechday.ch

SWISS BIOTECH DAY 2016

The leading Life Sciences Conference in Switzerland and Annual General Assembly of the Swiss Biotech Association



The Swiss Biotech Day is the leading biotechnology conference in Switzerland. Constantly growing, the 2016 event will bring together around 500 senior executives from the life science industry across Europe.

Programme highlights will be a keynote given by one of the thought leaders of the pharmaceutical industry, as well as the presentation of the 2016 Swiss Biotech Report.

Parallel sessions in the afternoon will focus on emerging biotechnology companies, publicly listed biotech companies, geographic hotspots in biotech and other topics.

Additionally, there will be an exhibition and extensive partnering opportunities with one-to-one meetings.

More information on the conference and a pre-registration form can be found at: www.swissbiotechday.ch



12 APRIL 2016

Basel Congress Center

Sponsors:



Organised by:



BIOCOM AG

In cooperation with:



Departement für Wirtschaft, Soziales und Umwelt des Kantons Basel-Stadt
Amt für Wirtschaft und Arbeit



Media Partner:

